AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2108908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 9
Study 2108908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7208538 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic mucilage with an 800 calorie hypoglucidic diet
Number of subjects: 22
Study 7208538 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 22
Study 31017851 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment for target morpheme
Number of subjects: 20
Study 31017851 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment for target morpheme
Number of subjects: 20
Study 31017851 — intervention group
Group type: COMPARATOR
Intervention: Control morpheme
Number of subjects: 20
Study 28903777 — intervention group
Group type: EXPERIMENTAL
Intervention: NF54-CPS immunization
Number of subjects: 39
Study 28903777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (uninfected mosquitoes)
Number of subjects: 39
Study 25406730 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg/week)
Number of subjects: 685
Study 25406730 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 685
Study 25406730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study 22982585 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm subjects (PT)
Number of subjects: 19
Study 22982585 — intervention group
Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 19
Study 21499201 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tidal volume (IV(T)) achieved by increasing inspired plateau pressure 0.04 cmH₂O kg⁻¹ above initial plateau pressure.
Number of subjects: 20
Study 21499201 — intervention group
Group type: COMPARATOR
Intervention: Normal tidal volume (NV(T)) with unchanged end‐tidal carbon dioxide partial pressure (P(ET)CO₂).
Number of subjects: 20
Study 19704068 — intervention group
Group type: EXPERIMENTAL
Intervention: COPP/ABVD (arm A)
Number of subjects: 1196
Study 19704068 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP baseline (arm B)
Number of subjects: 1196
Study 19704068 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP escalated (arm C)
Number of subjects: 1196
Study 16838651 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose IFNalpha therapy (HDI)
Number of subjects: 0
Study 16838651 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose IFNalpha therapy (LDI)
Number of subjects: 0
Study 16838651 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta in combination with chemotherapy
Number of subjects: 0
Study 16838651 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta gene therapy
Number of subjects: 0
Study 15661439 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 42
Study 15661439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11872106 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial trigger-point massage therapy
Number of subjects: 30
Study 10094253 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued therapy with barbiturates, phenytoin, and valproate
Number of subjects: 1013
Study 10094253 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of carbamazepine
Number of subjects: 1013
Study 10094253 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of phenobarbitone
Number of subjects: 1013
Study 10094253 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antiepileptic drugs as monotherapy
Number of subjects: 1013
Study 10094253 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 1013
Study 9345394 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebif (recombinant human interferon beta) administered subcutaneously at a dose of 8 million international units (MIU) once a week for 2 years
Number of subjects: 0
Study 9345394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2179779 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response
Number of subjects: 46
Study 2179779 — intervention group
Group type: COMPARATOR
Intervention: Reading group
Number of subjects: 46
Study 2179779 — intervention group
Group type: COMPARATOR
Intervention: Charting group
Number of subjects: 46
Study 7430545 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin collyrium administered prior to surgery
Number of subjects: 20
Study 7430545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no indomethacin)
Number of subjects: 20
Study 31550863 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine combined with omeprazole
Number of subjects: 72
Study 31550863 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (Control)
Number of subjects: 72
Study 28007620 — intervention group
Group type: EXPERIMENTAL
Intervention: O2 group (received oxygen at 3 L/min via nasal prongs for three postoperative nights)
Number of subjects: 123
Study 28007620 — intervention group
Group type: EXPERIMENTAL
Intervention: O2 group
Number of subjects: 123
Study 28007620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oxygen)
Number of subjects: 123
Study 26156151 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided intervention
Number of subjects: 402
Study 26156151 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided intervention
Number of subjects: 402
Study 26156151 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent
Number of subjects: 402
Study 26156151 — intervention group
Group type: COMPARATOR
Intervention: Nobori biolimus-eluting stent
Number of subjects: 402
Study 24373253 — intervention group
Group type: COMPARATOR
Intervention: Cable TV intervention
Number of subjects: 0
Study 24373253 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive programming
Number of subjects: 0
Study 24373253 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced social support
Number of subjects: 0
Study 21450598 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 266
Study 21450598 — intervention group
Group type: COMPARATOR
Intervention: Late invasive strategy
Number of subjects: 266
Study 20037224 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning (cues provided without errors)
Number of subjects: 60
Study 20037224 — intervention group
Group type: COMPARATOR
Intervention: Trial‐and‐error learning (cues provided only after an error)
Number of subjects: 60
Study 20037224 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning in mild-to-moderate dementia group
Number of subjects: 60
Study 20037224 — intervention group
Group type: COMPARATOR
Intervention: Trial‐and‐error learning in mild-to-moderate dementia group
Number of subjects: 60
Study 17768180 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 billion heat-killed L. acidophilus LB plus 160 mg of spent culture medium
Number of subjects: 0
Study 17768180 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral rehydration solution
Number of subjects: 0
Study 15485934 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised care group (assertive outreach with evidence based biopsychosocial interventions)
Number of subjects: 144
Study 15485934 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 144
Study 11837149 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 16 micrograms/kg per minute
Number of subjects: 48
Study 11837149 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 32 micrograms/kg per minute
Number of subjects: 48
Study 11837149 — intervention group
Group type: COMPARATOR
Intervention: Control (10% intralipids at 16 micrograms/kg per minute and 20% intralipids at 32 micrograms/kg per minute)
Number of subjects: 48
Study 11837149 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol groups (both doses)
Number of subjects: 48
Study 9755260 — intervention group
Group type: COMPARATOR
Intervention: No cooling (control group; rectal temperature = 37.0 +/- 0.2 degreesC, n = 10)
Number of subjects: 22
Study 9755260 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal systemic cooling (rectal temperature = 36.3 +/- 0.2 degreesC, n = 6)
Number of subjects: 22
Study 9755260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild systemic cooling (rectal temperature = 35.7 +/- 0.2 degreesC, n = 6)
Number of subjects: 22
Study 7820891 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sodium alginate (Kaltostat)
Number of subjects: 92
Study 7820891 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove finger packs
Number of subjects: 92
Study 7820891 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin trouser packs
Number of subjects: 92
Study 7820891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nostrils packed for 48 hours
Number of subjects: 92
Study 7820891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nostrils packed for 24 hours
Number of subjects: 92
Study 7820891 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin gauze packs at 3 weeks
Number of subjects: 92
Study 7820891 — intervention group
Group type: EXPERIMENTAL
Intervention: Other packing materials at 3 weeks
Number of subjects: 92
Study 3134397 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol (decapeptyl for 30 days with pure FSH stimulation)
Number of subjects: 27
Study 3134397 — intervention group
Group type: COMPARATOR
Intervention: Short protocol (Buserelin for 15 days with pure FSH stimulation)
Number of subjects: 27
Study 3134397 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol
Number of subjects: 27
Study 3134397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 27
Study 30615009 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric overload (EOL) exercise
Number of subjects: 18
Study 30615009 — intervention group
Group type: COMPARATOR
Intervention: Control condition (10-minute cycling at 1 W·kg‐1)
Number of subjects: 18
Study 31095995 — intervention group
Group type: EXPERIMENTAL
Intervention: KET/DEX (0.7 μg/kg/h infusion of dexmedetomidine)
Number of subjects: 39
Study 31095995 — intervention group
Group type: COMPARATOR
Intervention: KET/FENT (three 25 μg fentanyl injections over 1.5 h)
Number of subjects: 39
Study 31095995 — intervention group
Group type: COMPARATOR
Intervention: Ketamine only administration
Number of subjects: 39
Study 29438092 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsatuzumab (600 mg) in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel
Number of subjects: 104
Study 29438092 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel
Number of subjects: 104
Study 27374839 — intervention group
Group type: COMPARATOR
Intervention: Stable renal function
Number of subjects: 301
Study 27374839 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 301
Study 27374839 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in renal function (IRF)
Number of subjects: 301
Study 27374839 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear increase in creatinine
Number of subjects: 301
Study 23417572 — intervention group
Group type: EXPERIMENTAL
Intervention: F/Sn/chitosan toothpaste (1,400 ppm F(-), 3,500 ppm Sn(2+), 0.5% chitosan)
Number of subjects: 10
Study 23417572 — intervention group
Group type: EXPERIMENTAL
Intervention: GelKam (3,000 ppm Sn(2+), 1,000 ppm F(-))
Number of subjects: 10
Study 23417572 — intervention group
Group type: EXPERIMENTAL
Intervention: F/Sn toothpaste (1,400 ppm F(-), 3,500 ppm Sn(2+))
Number of subjects: 10
Study 23417572 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (negative control)
Number of subjects: 10
Study 22410113 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-ceramic/veneer (Empress2/Eris or e.max Press core/e.max Ceram glaze)
Number of subjects: 31
Study 22410113 — intervention group
Group type: COMPARATOR
Intervention: Enamel antagonists
Number of subjects: 31
Study 22410113 — intervention group
Group type: COMPARATOR
Intervention: Enamel contralateral-antagonist
Number of subjects: 31
Study 22410113 — intervention group
Group type: EXPERIMENTAL
Intervention: All wear sites
Number of subjects: 31
Study 20457512 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 46
Study 20457512 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 46
Study 17628889 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional treatment
Number of subjects: 0
Study 17628889 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy, electrotherapy, ultrasound
Number of subjects: 0
Study 16305584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16305584 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg salbutamol (1 dose)
Number of subjects: 12
Study 16305584 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg salbutamol (2 doses)
Number of subjects: 12
Study 16305584 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOW inhalation (20 l min(‐1))
Number of subjects: 12
Study 16305584 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST inhalation (60 l min(‐1))
Number of subjects: 12
Study 16305584 — intervention group
Group type: EXPERIMENTAL
Intervention: LATE inhalation (slow inhalation after 5 s)
Number of subjects: 12
Study 12079631 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.45 microm diode laser with cryogen spray cooling, average power 12 W, treated on three separate occasions 3 weeks apart.
Number of subjects: 9
Study 12079631 — intervention group
Group type: COMPARATOR
Intervention: Cryogen spray cooling alone, treated on the contralateral sides as control.
Number of subjects: 9
Study 10442547 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 microg twice daily for 12 weeks
Number of subjects: 0
Study 10442547 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 microg once daily for 12 weeks
Number of subjects: 0
Study 10442547 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 microg once daily for a further 12 weeks
Number of subjects: 0
Study 10442547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7778170 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG (ATGAM) administered in variable doses to maintain the absolute number of peripheral CD3 T cells at 50-100/microliters (Group 1)
Number of subjects: 45
Study 7778170 — intervention group
Group type: COMPARATOR
Intervention: ATG given at a fixed dose of 15 mg/kg/day (Group 2)
Number of subjects: 45
Study 7778170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received azathioprine and prednisone
Number of subjects: 45
Study 7778170 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (variable dosing) vs Group 2 (fixed dosing)
Number of subjects: 45
Study 2088233 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg for 14 days)
Number of subjects: 16
Study 2088233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 104724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium 2-mercapto-ethane sulphonate aerosol
Number of subjects: 11
Study 104724 — intervention group
Group type: COMPARATOR
Intervention: Saline aerosol (placebo)
Number of subjects: 11
Study 30720382 — intervention group
Group type: EXPERIMENTAL
Intervention: eBook training
Number of subjects: 148
Study 30720382 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face training
Number of subjects: 148
Study 30940694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nalmefene (3 mg) with dodecyl maltoside
Number of subjects: 0
Study 30940694 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular nalmefene (1.5 mg)
Number of subjects: 0
Study 29894921 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) - 60-minute session
Number of subjects: 130
Study 29894921 — intervention group
Group type: COMPARATOR
Intervention: Reassurance - 15-minute session
Number of subjects: 130
Study 29894921 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study 26829933 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (1 x 20 Gy)
Number of subjects: 386
Study 26829933 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (1 x 8 Gy)
Number of subjects: 386
Study 24144736 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 351
Study 24144736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no statin therapy)
Number of subjects: 351
Study 24144736 — intervention group
Group type: COMPARATOR
Intervention: Age >70 years
Number of subjects: 351
Study 24144736 — intervention group
Group type: COMPARATOR
Intervention: History of cardiac disease
Number of subjects: 351
Study 24144736 — intervention group
Group type: COMPARATOR
Intervention: Moderate/severe tobacco use
Number of subjects: 351
Study 23192500 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.8% milk
Number of subjects: 90
Study 23192500 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 90
Study 23192500 — intervention group
Group type: COMPARATOR
Intervention: 0.1% gastrografin
Number of subjects: 90
Study 21036355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Number of subjects: 658
Study 21036355 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 ethyl esters 90 2g
Number of subjects: 658
Study 21036355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study 21036355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin in low cholesterol synthesisers with high absorption
Number of subjects: 658
Study 17337382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment using HDAC inhibitors and PPARγ agonists
Number of subjects: 0
Study 17337382 — intervention group
Group type: COMPARATOR
Intervention: PPARγ agonists (thiazolidinediones)
Number of subjects: 0
Study 16351564 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months at altitude (4,500 m)
Number of subjects: 0
Study 16351564 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 months at altitude (4,500 m)
Number of subjects: 0
Study 17251695 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 171
Study 17251695 — intervention group
Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 171
Study 10937517 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (150 mg orally at bedtime)
Number of subjects: 6
Study 10937517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8990407 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 0
Study 8990407 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0
Study 8990407 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional procedures
Number of subjects: 0
Study 8990407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention within the first 3 days post-MI
Number of subjects: 0
Study 1353350 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk/stair climb (experimental group)
Number of subjects: 40
Study 1353350 — intervention group
Group type: COMPARATOR
Intervention: Walk/stand activity protocol (control group)
Number of subjects: 40
Study 6373264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol slow release 160 mg b.i.d.
Number of subjects: 1741
Study 6373264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study 6373264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol slow release 160 mg b.i.d. in patients <65 years
Number of subjects: 1741
Study 6373264 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients <65 years
Number of subjects: 1741
Study 6373264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol slow release 160 mg b.i.d. in patients <65 years continuing medication
Number of subjects: 1741
Study 6373264 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients <65 years continuing medication
Number of subjects: 1741
Study 31179743 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy in PD-L1-low-radioresistant (RR) group
Number of subjects: 0
Study 31179743 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment in PD-L1-low-RR group
Number of subjects: 0
Study 31179743 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF19 and PLA2G5 expression in PD-L1-low-RR group
Number of subjects: 0
Study 30515654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm collected at the middle of spawning period
Number of subjects: 100
Study 30515654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm collected at the beginning of spawning period
Number of subjects: 100
Study 30515654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm volume measurements
Number of subjects: 100
Study 30515654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm density measurements
Number of subjects: 100
Study 30515654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm velocity measurements
Number of subjects: 100
Study 30515654 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of motile sperm
Number of subjects: 100
Study 27557813 — intervention group
Group type: EXPERIMENTAL
Intervention: Social environmental intervention (group motivational interviewing delivered by team leaders)
Number of subjects: 329
Study 27557813 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical environmental intervention (environmental modifications)
Number of subjects: 329
Study 24989892 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and chemotherapy (arms B and C)
Number of subjects: 1325
Study 24989892 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (arm C)
Number of subjects: 1325
Study 24989892 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (arm A)
Number of subjects: 1325
Study 22897892 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm Pacing (DP) in addition to Non Invasive Ventilation (NIV)
Number of subjects: 108
Study 22897892 — intervention group
Group type: COMPARATOR
Intervention: Non Invasive Ventilation (NIV)
Number of subjects: 108
Study 20427981 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 1000
Study 20427981 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal intensity of RRT
Number of subjects: 1000